Skip to content

Reporting Hub

Three colleagues wearing masks and standing in front of a wall full of sticky notes look at a tablet device
Home
Reporting Hub
2021 ESG Performance Data

ESG Performance Data

The following ESG Performance Data is also available as an Excel download.

Financial Results

Financial Results (Millions) 2021 2020 2019
Total sales $93,775 $82,584 $82,059
Net earnings $20,878 $14,714 $15,119
Market price per share (year-end close) $171.07 $157.38 $145.87
R&D investment $14,714 $12,159 $11,355
Sales by business segment
placeholder
placeholder
placeholder
Pharmaceutical $52,080 $45,572 $42,198
MedTech $27,060 $22,959 $25,963
Consumer Health $14,635 $14,053 $13,898
Number of consecutive years of dividend increases1 60 59 58

Tax Contribution (Billions)

Tax Contribution (Billions) 2021 2020 2019
Payroll & social insurance taxes borne $1.5 $1.3
placeholder
Payroll & social insurance taxes collected $4.6 $4.3
placeholder
Sales/use & other taxes borne $0.9 $0.8
placeholder
Sales/use & other taxes collected $1.3 $1.0
placeholder
Corporate income tax $4.8 $4.6
placeholder
Total taxes borne $7.2 $6.7
placeholder
Total taxes collected $6.0 $5.3
placeholder
Total tax contribution $13.1 $12.0
placeholder
1 Includes dividend declared in April 2022.

Global Health Equity

VERMOX Donations
placeholder
placeholder
2021
Number of VERMOX (mebendazole) doses donated (millions)
placeholder
placeholder
placeholder
Annual total1
placeholder
placeholder
220.71
Via donations to the WHO
placeholder
placeholder
144
Via other and private donations
placeholder
placeholder
77
Cumulative doses donated since the start of the initiative through the WHO and private donations (billions)
placeholder
placeholder
2.0
Number of countries where VERMOX (mebendazole) doses were donated
placeholder
placeholder
55

Access to Tuberculosis Treatment

Access to Tuberculosis Treatment 2021 2020 2019
Annual number of patients receiving access to bedaquiline molecule (branded and generic) 137,927 133,565 105,365

Access to Medicine

Access to Medicine 2021 2020 2019
Number of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme 6 6 6
Number of products on the WHO List of Prequalified Vaccines as part of its Prequalification of Vaccine Programme 2 0 0
% change in average net price across U.S. product portfolio vs. prior year2 (2.8)% (5.7)% (1.2)%

Our Giving (Millions)

Our Giving (Millions) 2021 2020 2019
Total products and cash contributed $2,738 $2,567+ $1,806+
Products contributed $2,303 $2,043+ $1,383+
Cash contributed $435 $524+ $423+

Disaster Relief (Millions)

Disaster Relief (Millions) 2021 2020 2019
Total allocated for immediate, mid- and long-term response and readiness to natural disasters $0.29 $0.57 $0.70
$ worth of Johnson & Johnson products provided to communities impacted by natural disasters $6.69 $1.86 $36.70
See PwC’s Report of Independent Accountants and Management's Assertion.
+ See PwC's Report of Independent Accountants in the 2020 and 2019 Health for Humanity Report.
1 2021 doses donated include VERMOX (mebendazole) chewable and tablet formulations.
2 Represents the year-over-year change in the average net price, which is list price less rebates, discounts and fees.

Our Employees

Global Employees 2021 2020 2019
Total number of employees1, 2 144,315 136,360+ 137,701+
Women 49.0% 48.1%+ 47.8%+
Men 50.9% 51.9% 52.2%
Declined to answer1 0.1% 0% Not reported
Region
placeholder
placeholder
placeholder
Asia Pacific 29,517 27,939+ 28,195+
Europe, Middle East & Africa 42,429 41,201+ 42,582+
Latin America 23,441 20,320+ 20,182+
North America 48,928 46,900+ 46,742+

Gender Representation

Gender Representation 2021 2020 2019




Women Men Declined to answer1

Women Men ‎Declined to answer1

Women Men Declined to answer1
Region
placeholder
placeholder
placeholder

Asia Pacific
47.4%52.6%0%
46.2%+53.8%0%
46.0%+54.0%Not reported

Europe, Middle East & Africa
50.3%49.7%0%
49.8%+50.2%0%
49.7%+50.3%Not reported

Latin America
53.3%46.7%0%
51.1%+48.9%0%
50.2%+49.8%Not reported

North America
46.9%52.9%0.2%
46.3%+53.6%0%
46.1%+53.9%Not reported
Employment type
placeholder
placeholder
placeholder

Full-time employees
48.1%51.8%0.1%
47.1%+52.9%0%
46.7%+53.3%Not reported

Part-time employees
83.5%16.5%0%
82.9%+17.1%0%
82.6%+17.4%Not reported
Job category3
placeholder
placeholder
placeholder

Vice Presidents
38.9%60.9%0.2%
35.3%+64.7%0%
34.2%+65.8%Not reported

Managers and Directors4

48.3%51.7%0.1%
46.8%+53.2%0%
46.2%+53.8%Not reported
Professionals4

50.5%49.4%0%
49.8%+50.2%0%
49.5%+50.5%Not reported
Management and Executive Positions3
placeholder
placeholder
placeholder
Women in management positions
48.0%
46.4%+
45.8%+
Women in executive positions
14.3%
14.3%+
14.3%+

Diversity in Board Composition

Diversity in Board Composition 2021 2020 2019
Women 35.7% 35.7%+ 28.6%+
Ethnic/Racial diversity 21.4% 21.4%+ 21.4%+

Age Diversity by Job Category

Age Diversity by Job Category 2021 2020 2019
Vice Presidents
placeholder
placeholder
placeholder
Under 30 0% 0%+ 0%+
30 – 50 43.5% 44.2%+ 46.3%+
51+ 56.5% 55.8%+ 53.7%+
Managers and Directors
placeholder
placeholder
placeholder
Under 30 1.5% 1.3%+ 1.3%+
30 – 50 72.2% 72.4%+ 73.2%+
51+ 26.3% 26.4%+ 25.6%+
Professionals
placeholder
placeholder
placeholder
Under 30 22.7% 20.7%+ 21.4%+
30 – 50 60.0% 61.7%+ 61.7%+
51+ 17.3% 17.5%+ 16.9%+

Ethnic/Racial Diversity in the U.S. by Job Category

Ethnic/Racial Diversity in the U.S. by Job Category 2021 2020 2019
Vice Presidents
placeholder
placeholder
placeholder
White 70.7% 72.7% 75.4%
Asian 11.7% 11.2% 10.4%
Black/African American 7.3% 6.6% 6.7%
Hispanic/Latino 8.3% 8.4% 6.9%
Other 1.9% 0.9% 0.6%
Declined to answer1 0.1% 0.1% Not reported
Managers and Directors4
placeholder
placeholder
placeholder
White 64.5% 67.7% 70.2%
Asian 18.3% 17.2%+ 16.6%+
Black/African American 6.3% 5.4%+ 5.0%+
Hispanic/Latino 7.7% 7.3%+ 7.0%+
Other 1.9% 1.3%+ 1.2%+
Declined to answer1 1.4% 1.1%+ Not reported
Professionals
placeholder
placeholder
placeholder
White 64.2% 66.4% 68.0%
Asian 13.4% 12.9%+ 12.0%+
Black/African American 7.7% 7.5%+ 7.6%+
Hispanic/Latino 10.4% 10.2%+ 10.4%+
Other 2.5% 2.2%+ 2.0%+
Declined to answer1 1.8% 0.9%+ Not reported

New Employee Hires

New Employee Hires 2021 2020 2019
Total Number of New Hires 22,543 13,594+ 21,948+
Region4
placeholder
placeholder
placeholder
Asia Pacific 25.6% 28.4%+ 28.9%+
Europe, Middle East & Africa 16.7% 22.7%+ 27.0%+
Latin America 29.2% 22.4%+ 16.5%+
North America 28.4% 26.4%+ 27.6%+
Gender representation
placeholder
placeholder
placeholder
Women 54.0% 52.5%+ 51.4%+
Men 45.8% 47.5%+ 48.6%+
Declined to answer1 0.2% 0%+ Not reported
Age
placeholder
placeholder
placeholder
Under 30 47.5% 46.5%+ 52.7%+
30 – 50 47.6% 48.5%+ 42.8%+
51+ 4.9% 4.9%+ 4.5%+

Employee Retention and Turnover

Employee Retention and Turnover 2021 2020 2019
Managers5 and above moved across functions, country or business segment lines 45.8% 44.6%+ 42.6%+
Overall voluntary turnover 8% 5%+ 8%+
Voluntary turnover of high performers 4% 3%+ 4%+

Parental Leave

Parental Leave 2021 2020 2019
Gender composition of U.S. employees who took parental leave
placeholder
placeholder
placeholder
Women 43% 45% 47%
Men 57% 55% 53%
Gender composition of U.S. employees who returned to work after parental leave ended
placeholder
placeholder
placeholder
Women 93% 97% 98%
Men 89% 97% 100%

Year-End Performance Reviews Completed by Job Category

Year-End Performance Reviews Completed by Job Category 2021 2020 2019
Vice Presidents 87% 83% 76%
Managers and Directors 94% 93% 90%
Professionals 95% 93% 90%
Other6 87% 88% 82%
Overall for all employees 94% 93% 89%

Training & Development

Training & Development 2021 2020 2019
Number of leaders participated in our Enterprise Leader Development Program (annual) 1,929 3,206 3,537
Number of leaders trained in our Enterprise Leader Development Program (cumulative) 13,131 11,202 7,996
Number of U.S. and Puerto Rico employees participated in the tuition reimbursement program 1,189 1,178 1,262

Spend on Employee Learning and Development (Millions)

Spend on Employee Learning and Development (Millions) 2021 2020 2019
Leadership training and executive coaching $64 $18 $27
Professional skills $63 $56 $52
Tuition and external certifications $11 $16 $11
Operations, administration and e-learning $10 $17 $7
Health Care Compliance training $2 $2 $2
Total $150 $108 $98

2021 Our Voice Survey Results

2021 Our Voice Survey Results
placeholder
placeholder
2021
Number of languages available
placeholder
placeholder
36
Number of countries administered
placeholder
placeholder
77
Response rate (among all active employees)
placeholder
placeholder
91%
Increase in participation compared to 2019 (among all eligible employees)
placeholder
placeholder
1%
Favorability rate
placeholder
placeholder
82%
Increase in favorability compared to 2019 on like-to-like questions
placeholder
placeholder
2%
Percentage agreed with the statement:
placeholder
placeholder
placeholder
I am willing to give extra effort to help Johnson & Johnson meet its goals.
placeholder
placeholder
94%
I would recommend Johnson & Johnson as a great place to work.
placeholder
placeholder
87%
In my workgroup, we eliminate practices that stand in the way of achieving results.
placeholder
placeholder
71%
I would like to be working at Johnson & Johnson one year from now.
placeholder
placeholder
91%
Leaders in my organization demonstrate that integrity, quality and compliance are top priorities through their words and actions.
placeholder
placeholder
86%

Employee Resource Groups (ERGs)

Employee Resource Groups (ERGs) 2021 2020 2019
Number of employees engaged in ERGs 28,135 24,304 21,611
Number of U.S. ERG chapters 270 260 255
Number of non-U.S. ERG chapters 208 183 176
Number of WeSustain teams (global) 78 Not reported Not reported
Number of countries with WeSustain teams 32 Not reported Not reported
Number of actions taken in 2021 via the HealthyPlanet platform 24,609 Not reported Not reported

Employee Safety

Employee Safety 2021 2020 2019
Employee Safety,7 Global
placeholder
placeholder
placeholder
Lost Workday Case rate8 0.06 0.05+ 0.07+
Total Recordable Injury Rate 0.30 0.24+ 0.31+
Serious Injury and Illness Case rate 0.02 0.02+ 0.04+
Number of fatalities 0 0+ 0+
Employee Safety7 by Region
placeholder
placeholder
placeholder
Lost Workday Case rate8
placeholder
placeholder
placeholder
Asia Pacific 0.06 0.02+ 0.06+
Europe, Middle East & Africa 0.06 0.04+ 0.05+
Latin America 0.07 0.08+ 0.06+
North America 0.07
0.07+
0.08+
Total Recordable Injury Rate
placeholder
placeholder
placeholder
Asia Pacific 0.14 0.08+ 0.12+
Europe, Middle East & Africa 0.29 0.21+ 0.27+
Latin America 0.26 0.18+ 0.25+
North America 0.37 0.35+ 0.42+
Serious Injury and Illness Case rate
placeholder
placeholder
placeholder
Asia Pacific 0.01 0.02+ 0.04+
Europe, Middle East & Africa 0.02 0.01+ 0.03+
Latin America 0.02 0.01+ 0.02+
North America 0.04 0.04+ 0.06+

Road Safety

Road Safety9 2021 2020 2019
Crashes per Million Miles (CPMM) rate 4.83 4.86 5.54
Injuries per Million Miles (IPMM) rate 0.07 0.05 0.06
See PwC’s Report of Independent Accountants and Management's Assertion.
+ See PwC's Report of Independent Accountants in the 2020 and 2019 Health for Humanity Report.
1 As of October 2020, new categories were added to allow employees to actively decline self-identification or remain unidentified. Where the value for 'Declined to answer' rounded to zero, we excluded from the reported table.
2 “Employee” is defined as an individual working full-time or part-time, excluding fixed-term employees, interns and co-op employees. Employee data may not include full population from more recently acquired companies, and individuals on long-term disability are excluded. Contingent workers, contractors and subcontractors are also excluded. Fixed-term contracts make up less than 5% of total employees plus individuals on fixed-term contracts. Johnson & Johnson is not currently able to disclose the number of individuals on fixed-term contracts in 2021. We are working to make this information available in future.
3 Professional positions are defined as pay grades 20-26. Management positions are defined as pay grade 30 and above; executives are defined as employees reporting directly to the CEO.
4 Values have been rounded to the nearest tenth. Due to rounding, the numbers presented do not add up precisely to the totals provided, and percentages may not precisely reflect the absolute figures.
5 Career progression movement includes upward promotion and lateral transfer, and excludes employees in the R&D organizations.
6 Category includes employees who don’t have a merit plan as part of their compensation package.
7 LWDC rate, TRIR, SIIC rate, and fatalities are calculated for Johnson & Johnson employees and contingent workers. Contingent workers (i.e., workers supplied by third-party agencies that are the worker’s employer of record) are intended to supplement or temporarily replace existing workforce and are directly supervised by a Johnson & Johnson employee.
8 “Lost days” are calendar days counted beginning the day after an incident has taken place.
9 CPMM and IPMM rates are based on Safe Fleet data. Rate calculation methodology uses both actual and estimated data on miles driven. We collect Safe Fleet data on employees who drive Company-owned or -leased and personally owned vehicles for Company business. Employees in the latter category are those who: 1) drive for Company business as a “regular part“ of their job duties, and 2) receive a car allowance to purchase their own vehicle and/or are reimbursed for vehicle expenses such as fuel, maintenance, insurance and other miscellaneous charges associated with vehicle upkeep.

Environmental Health

Energy Use1 2021 2020 2019
Total energy use (TJ) 11,947 11,954 12,702
From renewable sources 3,355 3,483 2,118
From non-renewable sources 8,593 8,471 10,584
Energy intensity ratio (TJ/billion $)2 127 145 155
Percentage change in energy intensity compared to 2016 baseline (TJ/billion $)3 (29)% (19)% (13)%
Percent renewable electricity by region
placeholder
placeholder
placeholder
North America 67% 72% Not reported
Europe 79% 82% Not reported
Purchased energy use by type (TJ)1
placeholder
placeholder
placeholder
Electricity 5,885 5,922 6,421
Natural gas 4,480 4,412 4,808
Diesel 507 613 465
Direct heating/cooling 312 265 274
Propane 44 53 51
Biogas 31 28 26
Fuel oil 9 13 15
Total purchased energy 11,267 11,306 12,059
On-site generated energy use by type (TJ)1
placeholder
placeholder
placeholder
Co-generation 456 418 439
Wind 111 129 97
Solar PV 86 73 78
Geothermal 21 18 6
Fuel cell 4 7 22
Biomass 3 2 2
Total on-site generated energy 681 647 643
On-site clean/renewable energy capacity by type4
placeholder
placeholder
placeholder
Solar PV 44% 37% 39%
Co-generation 29% 32% 31%
Wind 23% 25% 25%
Geothermal 2% 3% 2%
Biomass 2% 2% 2%
Fuel cell 1% 1% 1%
On-site clean/renewable energy technology capacity, (MW) 67.2 61.4 62.7
Electricity generated from renewable sources 52% 54% 30%

Environmental Health

Greenhouse Gas (GHG) Emissions 2021 2020 2019
Scope 1 GHG emissions, total (MT CO2e)5 367,674 363,686 426,074
Scope 1 GHG emissions by source (MT CO2e)5
placeholder
placeholder
placeholder
Facilities1 264,669 268,448 288,200
Sales fleet16 81,093 76,720 114,681
Refrigerants17 13,569 14,139 12,979
Aviation 8,344 4,378 10,215
Scope 2 GHG emissions, facilities (MT CO2e)1, 5
placeholder
placeholder
placeholder
Location-based 616,093 610,320 629,674
Market-based6 397,086 383,480 542,756
Scope 1 + Scope 2 GHG emissions, total (MT CO2e) 764,760 747,166 968,830
GHG emissions intensity (Scope 1 + Scope 2) by revenue (MT CO2e/million $) 8 9 12
Percentage decrease in GHG emissions intensity (Scope 1 + Scope 2) by revenue compared to 2016 baseline (MT CO2e /million $) 50% 44% 27%
Scope 3 GHG emissions, by source (MT CO2e)5, 15
placeholder
placeholder
placeholder
Purchased goods and services7 6,605,416 6,244,849 6,211,425
Upstream transportation and distribution7 1,541,624 1,456,295 1,512,901
Business travel7, 8 225,317 218,535 757,832
Employee commuting9 117,192 131,128 267,881
Capital goods7 207,060 201,126 222,883
Fuel- and energy-related activities10 241,021 183,087 190,386
Upstream leased assets11 24,657 28,969 39,830
Waste generated in operations12 8,759 8,065 3,618
Downstream transportation and distribution13 Available 12/22 55,332 58,184
Use of sold products17
placeholder
placeholder
placeholder
Direct 76,721 108,165 168,612
Indirect 8,087,123 7,635,771 7,248,612
End-of-life treatment of sold products14 223,963 223,038 209,994

Restatement of Select Scope 3 Categories by Source (MT CO2e)5, 15

Restatement of Select Scope 3 Categories by Source (MT CO2e)5, 15 2018 2017 2016
Purchased goods and services7 6,166,870 5,775,434 5,937,694
Upstream transportation and distribution7 1,464,439 1,389,387 1,384,751
Business travel7, 8 872,399 777,550 823,258
Capital goods7 198,575 174,014 173,646

Capital Relief Fund

CO2 Capital Relief Fund 2021 2020 2019
Number of projects approved 11 16 16
Number of projects completed 19 10 14
Cumulative projects approved since 2005 291 280 266
Cumulative projects completed since 2005 260 241 231
Amount spent on projects, annual (millions) $24 $33 $25
Cumulative spend on completed projects since 2005 (millions) $470 $445 $431
Total annual energy cost savings as a result of completed projects since 2005 (millions) $87 $83 $80
Total annual energy savings as a result of completed projects since 2005 (TJ)18 2,512 2,345 2,247
Total annual GHG emissions avoided as a result of completed projects since 2005 (MT CO2e) 313,965 298,905 287,931

Air Emissions (MT)

Air Emissions (MT) 2021 2020 2019
Hazardous air pollutant (HAP) emissions 43.35 34.62 39.98
Mono-nitrogen oxides (NOx) emissions 37 45 35
Ozone-depleting substances emissions 1.28 1.86 1.11
Ozone-depleting substances emissions
(MT of CFC-11 equivalents)
0.05 0.09 0.05
Particulate matter (PM) emissions 67.10 89.20 116.56
Refrigerant emissions 8.65 9.58 8.01
Sulfur oxides (SOx) emissions 53 65 51
Volatile organic compound (VOC) emissions 449.15 366.08 394.07

Water Use (Million m3)

Water Use (Million m3) 2021 2020 2019
Total water withdrawn 11.04 11.09 11.71
Total water consumed19 3.89 3.77 4.01
Total water recycled and reused 0.81 0.75 0.81
Total water discharge19 7.15 7.32 7.67
Percentage of water withdrawn in regions of high or extremely high baseline water stress 40% 39% 39%
Percentage of water consumed in regions of high or extremely high baseline water stress 52% 50% 48%
Water withdrawn by source
placeholder
placeholder
placeholder
Municipal 7.70 7.72 8.68
Groundwater 3.06 3.08 2.85
Other 0.09 0.06 0.07
Rainwater 0.15 0.06 0.03
Gray water 0.02 0.15 0.06
Surface water 0.01 0.02 0.02
Total water use 11.04 11.09 11.71
Water withdrawn in areas of high or extremely high baseline water stress by source
placeholder
placeholder
placeholder
Municipal 3.20 Not reported Not reported
Groundwater 1.02 Not reported Not reported
Rainwater 0.13 Not reported Not reported
Other 0.09 Not reported Not reported
Gray water 0.01 Not reported Not reported
Surface water 0 Not reported Not reported
Total water use in areas of high or extremely high baseline water stress
4.45 Not reported Not reported
Water discharge by destination
placeholder
placeholder
placeholder
Wastewater treatment plant 4.81 5.12 5.46
Surface water 1.85 2.00 2.12
Irrigation 0.26 0.19 0.19
Ocean 0.18 0.18 0.12
Other 0.06 0.07 0.06
Total water discharge 7.15 7.56 7.95

Operational Waste (MT)

Operational Waste (MT) 2021 2020 2019
Total waste generated20 194,836 183,558 195,272
Hazardous waste 52,180 53,944 53,425
Non-hazardous waste20 142,656 129,614 141,848
Waste diverted from disposal
placeholder
placeholder
placeholder
Hazardous waste
placeholder
placeholder
placeholder
Recycled 25,207 22,813 25,897
Energy recovery 16,599 19,836 16,684
Reused 1,457 2,234 1,756
Non-hazardous waste
placeholder
placeholder
placeholder
Recycled 92,206 82,184 83,118
Energy recovery 18,724 17,969 20,793
Reused 12,451 13,271 13,282
Total waste diverted from disposal 166,645 158,309 161,530
Waste directed to disposal
placeholder
placeholder
placeholder
Hazardous waste
placeholder
placeholder
placeholder
Landfilled 2,380 2,533 3,449
Incinerated 5,146 4,824 3,373
Bio/chemical treatment 1,269 1,599 2,181
Other 121 104 86
Non-hazardous waste
placeholder
placeholder
placeholder
Landfilled20 9,424 8,384 12,512
Incinerated 1,965 2,799 2,923
Bio/chemical treatment 7,808 4,948 9,192
Other 78 59 28
Total waste directed to disposal 28,192 25,250 33,744

EH&S Compliance and Certifications

EH&S Compliance and Certifications 2021 2020 2019
Number of manufacturing and R&D sites certified to ISO 1400121, 22 92 95+ 100+
Percentage of manufacturing and R&D sites certified to ISO 1400121, 22 89% 96%+ 97%+
Percentage of manufacturing and R&D sites certified to ISO 4500121, 22 17% 21%+ 24%+
Number of environmental non-compliances23, 24 34 50+ 61+
Fines paid for environmental non-compliances (thousands)24, 25 $3.6 $5.9+ $41+

LEED Buildings

LEED Buildings 2021 2020 2019
Number of newly LEED-certified Johnson & Johnson buildings (annual) 7 6 2
Number of Johnson & Johnson buildings that are LEED-certified (total) 67 60 54
Percentage of Johnson & Johnson built space that is LEED-certified (total) 15.9% 14.5% 13%
Total area of office and building space that is LEED certified (million square feet) 9.4 8.7 8.0

Product End of Life (Millions)

Product End of Life (Millions) 2021 2020 2019
Number of medical devices collected in U.S. 0.93 1.60 2.45
Number of medical devices reprocessed in U.S. 0.39 0.67 1.12
Metric has been assured by ERM CVS. See GHG Emissions, Electricity and Water Data - ERM CVS.
See ERM CVS's independent assurance statements in the 2019 and 2020 Health for Humanity Report.
See PwC’s Report of Independent Accountants and Management's Assertion.
+ See PwC's Report of Independent Accountants in the 2019 and 2020 Health for Humanity Report.
1 Includes site-specific data from all Johnson & Johnson owned and leased sites over 50,000 square feet where Johnson & Johnson has operational control as well as manufacturing and R&D sites under 50,000 square feet, unless otherwise noted.
2 Our diverse product portfolio makes it difficult to track an organization-specific metric; therefore, we use revenue as a denominator for energy intensity. Energy intensity ratio includes electricity, stationary fuels and district heating and cooling.
3 2019 and 2020 figures are restated to reflect updated baseline.
4 Values have been rounded to the nearest whole number. Due to rounding, the numbers presented do not add up precisely to the totals provided, and percentages may not precisely reflect the absolute figures.
5 In accordance with guidance from World Resources Institute Corporate Accounting and Reporting Standard, we restated the 2019 and 2020 values to reflect newly released electricity grid emission factors as well as the addition or removal of acquisitions and divestitures. This threshold for restatement deviates from the one included in the About This Report section. We do not currently use purchases, sales or transfers of offsets in our GHG accounting. Gases covered in these calculations include CO2, CH4, N2O and HFCs. Perfluorinated chemicals, sulfur hexafluoride and nitrogen trifluoride do not result from our operations. Biogenic CO2 emissions in 2021 were 1,758 MT CO2. Electricity emission factors are obtained from the International Energy Agency’s CO2 Emissions from Fuel Combustion Report; the U.S. Environmental Protection Agency's eGRID publication for location-based Scope 2 reporting, and supply contracts and residual emission factors, where available, for market-based Scope 2 reporting. Fuel emission factors are obtained from the EPA Climate Leadership publication. Global Warming Potentials are obtained from the Intergovernmental Panel on Climate Change Fifth Assessment Report. The chosen consolidation approach for emissions is operational control.
6 We did not report Scope 2 emissions using the market-based method prior to 2017. Starting from 2017, we have reported Scope 2 emissions using both location-based and market-based methods, based on the latest Scope 2 guidance from the World Resources Institute in the Corporate Accounting and Reporting Standard.
7 2016-2020 data for certain Scope 3 upstream categories is restated to adjust for inflation. Emissions were calculated using Company spend in the reporting year paired with appropriate economic input/output (IO) emission factors from the Carnegie Mellon 2002 data set. Where more specific primary data were able to be obtained, they were used in place of the IO calculation methodology.
8 Business travel emissions from personal vehicle travel reflect CO2 only.
9 Data from a 2021 survey of a sample of employees in all regions, extrapolated for all employees globally, were used to estimate average employee commuting and remote working emissions intensity per employee. This value was used to calculate 2021 emissions from Employee Commuting.
10 Emissions from fuel- and energy-related activities were calculated for emissions from transmission and distribution (T&D) losses from purchased electricity, well-to-tank (WTT) emissions from purchased electricity, WTT emissions from T&D losses, and WTT emissions from purchased fuels. Emissions were calculated using IEA loss factors for electricity and DEFRA WTT emission factors for fuels and electricity.
11 Emissions from Upstream Leased Assets were calculated by applying the energy intensity from office locations in our Scope 1 and Scope 2 footprint to the building area of leased assets less than 50,000 square feet, or those greater than 50,000 square feet outside of our operational control which are excluded from Scope 1 and Scope 2 reporting.
12 Emissions from Waste Generated in Operations were calculated for both non-hazardous and hazardous waste from manufacturing and R&D operations using DEFRA's emissions factors for waste. In years prior to 2020, only non-hazardous waste emissions were reported.
13 Emissions from Downstream Transportation and Distribution were calculated using the U.S. EPA’s SmartWay Program and are provided for U.S. shippers only. GHG covered in these calculations include CO2 only for the 2020 calendar year, the most up-to-date available. 2021 data will be available in December of 2022 and will be reported in future reports. We have identified a level of uncertainty around the reporting boundary, and the reported value is potentially overstated.
14 Emissions from the Use of Sold Products and the End-of-Life Treatment of Sold Products were calculated using sales volumes for all Johnson & Johnson products combined with lifecycle assessment (LCA) models where sales volumes could be obtained; where they could not be obtained, sales revenues and average unit prices were used to estimate volumes. Due to the size of our product portfolio, LCAs were not performed for every Johnson & Johnson product, so products were placed into LCA categories, and a representative product LCA was applied. It should be noted that due to the assumptions that were made, Johnson & Johnson did not receive third-party limited assurance for these scopes but will work to improve these assumptions in the coming years.
15 Emissions from the Processing of Sold Products, Downstream Leased Assets, Franchises and Investments are not applicable to Johnson & Johnson operations.
16 Greenhouse gases covered in these calculations include CO2 only.
17 Includes site-specific data from all Johnson & Johnson manufacturing and R&D sites only.
18 Results from completed projects. Based on fuel and electricity reduction calculations. Avoidance of energy consumption and GHG emissions calculated by comparing energy consumption before project implementation and expected consumption after implementation using engineering estimates at the time the projects are approved.
19 Due to a unit conversion error, 2019 and 2020 figures are restated.
20 2020 figures are restated.
21 Certified to ISO 14001 or ISO 45001 means the site has received an external certification that is valid as of December 31, 2021. The decrease in sites with ISO 14001 certifications is driven in part by a decrease in overall Johnson & Johnson-owned manufacturing and R&D sites.
22 The denominator of total manufacturing and R&D sites excludes small R&D and manufacturing sites (defined as having less than 50 employees) and newly acquired sites (i.e., owned less than three years as of December 31, 2021).
23 Environmental non-compliances represent instances of non-compliance with environmental regulatory requirements or laws that were either (i) self-reported to authorities in the reporting year or (ii) identified by authorities and the non-compliance occurred in the reporting year. The authorities include regional, national, state/country/province and local/city regulatory agencies.
24 Environmental non-compliances and fines paid exclude newly acquired sites (i.e., owned less than two years as of December 31, 2021).
25 Fines paid for environmental non-compliances include those paid in the reporting year. It does not include fines assessed and/or under negotiation that were not paid as of December 31, 2021.

Accountability & Innovation

Supply Base Overview 2021 2020 2019
Number of Johnson & Johnson suppliers 45,324 51,280 57,663
Total Johnson & Johnson supplier spend (billions)1 $34.8 $30.6 $30.1
Supplier spend contracted by region1
placeholder
placeholder
placeholder
Asia Pacific 9% 11% 11%
Europe, Middle East & Africa 34% 33% 33%
Latin America 3% 3% 4%
North America 55% 53% 52%
Supplier spend contracted by business segment1
placeholder
placeholder
placeholder
Pharmaceutical 37% 34% 31%
MedTech2 28% 24% 24%
Consumer Health2 24% 30% 32%
Corporate 12% 12% 13%

Supplier Engagement

Supplier Engagement 2021 2020 2019
Number of suppliers invited to participate in the CDP Supply Chain Climate program 388 423 344
Percentage participated 82% 80% 84%
Number of suppliers invited to participate in the CDP Supply Chain Water program 135 153 112
Percentage participated 75% 79% 84%
EcoVadis assessments completed3 881 1,119 750
Supplier risk ranking based on EcoVadis assessments
placeholder
placeholder
placeholder
Low risk 635 729 462
Medium risk 213 349 259
High risk 33 41 29

Diverse Supplier Spend in the U.S. (Millions)5

Diverse Supplier Spend in the U.S. (Millions)5 2021 2020 2019
Tier 1 Diverse $2,214 $1,670 $1,610
Total LGBT-owned $9.2 $4.5 $3.7
Total Veteran- and disabled veteran-owned $197.4 $193.2 $169.6
Small business $2,641 $2,650 $2,610
Percentage of total supplier spend attributable to small suppliers 14% 17% 18%
Percentage of total supplier spend attributable to diverse suppliers 12% 11% 11%
Total Global Impact Spend (billions)4 5.22 Not reported Not reported
% increase of Tier 1 diverse spend with U.S. Black- and Hispanic-owned businesses 31% Not reported Not reported

Diverse Supplier Spend, Global (Millions)5

Diverse Supplier Spend, Global (Millions)5 2021 2020 2019
Number of countries outside the U.S. tracking diversity & inclusion indicators 18 16 16
Tier 1 Women-owned $1,223.9 $826.0 Not reported
Tier 1 Minority-owned $1,785.1 $1,223.4 Not reported
Tier 1 LGBT-owned $11.0 Not reported Not reported
Tier 1 Veteran-owned and disabled veteran-owned $127.9 Not reported Not reported
Total Veteran-owned and disabled veteran-owned $206.3 Not reported Not reported
Tier 1 Diverse supplier spend in countries outside the U.S. $668.7 $290.0 Not reported
Total Tier 1 Diverse (billions) $2.9 Not reported Not reported
Tier 2 Diverse $508.7 $372.1 Not reported

Supplier Audits

Supplier Audits 2021 2020 2019
Supplier Environment, Health and Safety (EH&S) audits
placeholder
placeholder
placeholder
EH&S audits and technical visits completed, total 164 156 206
EH&S audits 124 104 134
Technical visits6 40 52 72
EH&S audits and technical visits by region
placeholder
placeholder
placeholder
Asia Pacific 133 133 174
Europe, Middle East & Africa 11 13 13
Latin America 10 2 7
North America 10 8 12
Number of suppliers identified as high risk for non-conformance to Johnson & Johnson Responsibility Standards for Suppliers 21 24 32
Number of critical EH&S findings7 identified as a result of EH&S audits 9 2 34
Safety-related findings 8 2 23
Environmental-related findings 1 0 11
Supplier social audits8
placeholder
placeholder
placeholder
Supplier social audits completed, total 11 5 50
Completed using SMETA 4-Pillar protocol 11 5 37
Social audits completed by region
placeholder
placeholder
placeholder
Asia Pacific 8 4 37
Europe, Middle East & Africa 2 0 5
Latin America 1 1 6
North America 0 0 2
Number of critical findings7 identified as a result of supplier social audits 1 3 5

Board of Directors' Composition

Board of Directors' Composition 2021 2020 2019
Number of Directors 14 14 14
Number of Independent Directors 13 13 13
Percentage of Independent Directors 93% 93% 93%
Independent Lead Director Yes Yes Yes
Independent Audit Committee Yes Yes Yes
Independent Compensation & Benefits Committee Yes Yes Yes
Independent Nominating & Corporate Governance Committee Yes Yes Yes
Independent Regulatory Compliance Committee Yes Yes Yes
Independent Science, Technology & Sustainability Committee Yes Yes Yes
Number of regular and special meetings held by the Board of Directors 17 10 9

Code of Business Conduct (CBC) Training

Code of Business Conduct (CBC) Training 2021 2020 2019
Percentage of active employees who completed biennial CBC training 98% Not reported 97%
Percentage of active contingent workers9 who completed biennial CBC training 97% Not reported 91%

Code of Business Conduct (CBC) Compliance

Code of Business Conduct (CBC) Compliance 2021 2020 2019
Percentage of senior leaders certified the compliance of their organizations with the CBC10 100% 100% 100%
Number of warning letters or untitled letters issued by OPDP or APLB in the U.S.11 0 0 0

Health Care Compliance (HCC) Training

Health Care Compliance (HCC) Training 2021 2020 2019
Number of relevant Johnson & Johnson employees that completed HCC training that includes anti-corruption section 98,000 81,000 90,000
Percentage of sales and marketing employees who completed HCC training 97% 96% 95%

Inquiries and Complaints as Recorded with Our Credo Integrity Line by Category13

Inquiries and Complaints as Recorded with Our Credo Integrity Line by Category13 2021 2020 2019
Human Resources-related 55% 51%+ 60%
Business integrity-related 14% 12%+ 6%
Other 9% 11%+ 8%
General information questions 8% 10%+ 11%
Financial-related 7% 14%+ 13%
Human rights-related 5% Not reported Not reported
Product quality- and patient safety-related 2% 2%+ 2%

Compliance-Related Allegations Investigated Through Triage Committee

Compliance-Related Allegations Investigated Through Triage Committee 2021 2020 2019
Number of compliance-related allegations investigated 661 559+ 738
Percentage of compliance-related allegations investigated by category
placeholder
placeholder
placeholder
Healthcare compliance 48% 41%+ 40%
Financial 43% 51%+ 50%
Other 9% 8%+ 10%

Collective Bargaining Agreements

Collective Bargaining Agreements 2021 2020 2019
Employees covered by collective bargaining agreements14 30% 23% 20%

Product Quality Indicators

Product Quality Indicators 2021 2020 2019
Number of regulatory inspections of Johnson & Johnson sites by worldwide health authorities 448 452+ 521+
Percentage of regulatory inspections that resulted in zero observations 76% 82%+ 73%+
Number of FDA inspections of Johnson & Johnson sites 9 10+ 17+
Percentage of FDA inspections that resulted in zero observations 56% 80%+ 76%+
Average number of observations per FDA inspection 2.4 1.7+ 0.6+
Number of independent audits of Johnson & Johnson sites to ensure compliance with Johnson & Johnson Quality Policy & Standards 170 165+ 156+
Number of independent audits of external manufacturing sites to ensure compliance with Johnson & Johnson Quality Policy & Standard 277 230+ 264+
Number of FDA warning letters issued 0 0+ 1+
Product recall rate15 by business segment
placeholder
placeholder
placeholder
Pharmaceutical 0% 0%+ 0.002%
MedTech 0.059% 0.034%+ 0.041%
Consumer Health Self-Care OTC16 0% 0%+ 0.091%

Anti-Counterfeiting

Anti-Counterfeiting 2021 2020 2019
Anti-counterfeiting best practices training delivered to customs and border patrol officials17 3,960 3,164 Not reported
Number of external trade groups, alliances, organizations and agencies in which Johnson & Johnson is engaged in leadership positions or industry working groups 13 7 9
Metric has been assured by ERM CVS. See Health for Humanity 2025 Goals - First Year of Progress - ERM CVS.
See PwC’s Report of Independent Accountants and Management's Assertion.
+ See PwC's Report of Independent Accountants in the 2020 and 2019 Health for Humanity Report.
1 Represents spend we have control over/addressable spend, defined as products and services that procurement teams can negotiate with suppliers to meet business goals. Values have been rounded. Due to rounding, the numbers presented do not add up precisely to the totals provided, and percentages may not precisely reflect the absolute figures.
2 Due to a categorization error, 2019 and 2020 figures are restated. Consumer MedTech supplier spend is included in the MedTech business segment. It had historically been reported as part of the Consumer Health business segment.
3 Supplier EcoVadis assessments are reported as of January 31 2022 may not capture suppliers that updated their assessment in January of 2022.
4 Total Global Impact Spend consists of: Tier 1 Diverse supplier spend in the U.S. (billions) and countries outside the U.S. (billions), plus Small business spend in the U.S. (billions), less overlap spend, plus Tier 2 diverse supplier spend, global (millions). U.S. suppliers can be classified as Tier 1 Diverse and Small business. The Tier 1 & Small overlap is removed to avoid double counting of the spend.
5 Except Tier 2 Diverse spend, all indicators represent spend Johnson & Johnson has control over/addressable spend, defined as products and services that procurement teams can negotiate with suppliers to meet business goals.
6 A technical visit is a follow-up visit to the initial audit.
7 We define a critical finding as evidence of very high risk to human life or potential catastrophic impact to facility, community or environment. We expect suppliers and potential suppliers to address critical findings immediately.
8 Social audits are conducted using the SMETA protocol. The PSCI protocol was phased out in 2020.
9 Temporary workers supplied by third-party agencies that are the workers' employer of record. Contingent workers are intended to supplement existing workforce or temporarily replace them.
10 Certifiers include senior leaders at VP2 level and above, selected Managing Directors and General Managers based on country or business segment risk profile, and executives of recently acquired companies.
11 OPDP: Office of Prescription Drug Promotion and APLB: Advertising and Promotional Labeling Branch of the FDA Center for Biologics Evaluation and Research.
13 Johnson & Johnson Triage Committee and case investigators have the ability to change the issue type of cases upon receipt in Our Credo Integrity Line. This occurs for 5% or fewer of cases.
14 The increase in percentage is not a reflection of new labor unions being recognized, but rather clarifying the definition of representation by labor union which expanded the qualifying population of certain countries in Asia and Latin America.
15 Product recall rate is defined as the number of lots removed from market per total globally manufactured, based on field action removals where it has been determined internally by a Quality Review Board, and aligned by Johnson & Johnson Enterprise Compliance, that there is a reasonable probability that the product may cause temporary or medically reversible adverse health consequences and, in certain cases, will cause serious adverse health consequences.
16 The Pharmaceutical and MedTech recall rate consider all products in each business segment. The Consumer Health product quality recall rate is inclusive of Consumer Health products from the Self-Care over-the-counter (OTC) business segment. It does not represent Essential Health and Skin Health/Beauty business segment products, including the voluntary recall of certain aerosol sunscreen products in 2021.
17 All employees at Johnson & Johnson are trained in the Code of Business Conduct as well as what to do if they become aware of a product complaint or adverse event. Brand protection awareness is included in both of these mandatory trainings to raise understanding and awareness of illicit trade issues among all employees. Supplemental brand protection training is also available to stakeholders and is reflected in the number above.
Previous Reporting Hub Next About this Report
Back to Top